SAN DIEGO, Oct. 20 /PRNewswire/ -- BIOCOM, the association for the life science community in Southern California, is proud to announce its first annual San Diego Investor Conference, to be held at the San Diego Marriott Del Mar November 14-16, 2006.
The San Diego Investor Conference will highlight both public and private investment opportunities in the region’s top life science companies to the nation’s top institutional and retail investors with more then 300 attendees expected. The two-day conference will include an opening reception, a full day of company presentations and one-on-one meetings, plenary sessions as well as bus tour around San Diego, visiting 10 different life science companies on the closing day of the conference.
“We are very excited to be hosting our first life science investor conference in Southern California,” said Joe Panetta, president and CEO of BIOCOM. “The strong showing of our presenters, investors, and sponsors shows the quality and diversity of the biotech, medical device and diagnostic companies in our life science community.”
Confirmed keynote speakers include William Rastetter, venture partner, Venrock Associates and former executive chairman of Biogen Idec and Karen Bernstein, founder, chairman and editor-in-chief of BioCentury. San Diego Mayor Jerry Sanders will start off the conference by welcoming attendees at the breakfast plenary on November 15th.
Scheduled presenting companies include: ACADIA Pharmaceuticals, Inc. (NasdaqGM:ACAD); ADVENTRX Pharmaceuticals, Inc. ; Althea Technologies, Inc.; Ambit Biosciences Corp.; AMN Healthcare Services ; Amylin Pharmaceuticals Corp., (NasdaqGS:AMLN); Anadys Pharmaceuticals, Inc. (NasdaqGM:ANDS); Arena Pharmaceuticals, Inc. (NasdaqGM:ARNA); Avanir Pharmaceuticals ; Cadence Pharmaceuticals; Cardium Therapeutics ; Ceregene, Inc.; Dexcom (NasdaqGM:DXCM); Digirad Corp. (NasdaqGM:DRAD); Diversa (NasdaqGM:DVSA); DJ Orthopedics ; Favrille, Inc. (NasdaqGM:FVRL); Gen-Probe, Inc. (NasdaqGS:GPRO); Halozyme Therapeutics, Inc. ; Hollis - Eden Pharmaceuticals (NasdaqGM:HEPH); Invitrogen (NasdaqGS:IVGN); Isis Pharmaceutical (NasdaqGM:ISIS); Metabasis Therapeutics, Inc. (NasdaqGM:MBRX); Novocell; Nuvasive, Inc. (NasdaqGM:NUVA); Opthonix; Phenomix; Quidel Corp. (NasdaqGM:QDEL); ResMed Corp. ; Santarus, Inc. (NasdaqGM:SNTS); Senomyx (NasdaqGM:SNMX); SGX Pharmaceuticals, Inc. (NasdaqGM:SGXP); Somaxon Pharmaceuticals, Inc. (NasdaqGM:SOMX); Spectrum Pharmaceuticals (NasdaqGM:SPPI); Verus Pharmaceuticals, Inc. and Vical (NasdaqGM:VICL).
Presenting companies are subject to change without notice. Please go to www.biocom.org to see the final list and schedule of presenting companies. The conference will cost $150 for institutional investors. Accredited media should contact BIOCOM about press passes to the conference.
The conference is being put on by BIOCOM, the association for the life science community in Southern California and CaliforniaStocks.com. Sponsors of the San Diego Investor Conference include Bank of America and UBS Investment Bank.
BIOCOM is the largest regional life sciences association in the world, representing 510 member companies in San Diego and Southern California. The association focuses on initiatives that positively influence the growth of the life science industry and the development and delivery of products that improve global health and quality of life. This includes initiatives in capital formation, public policy, workforce development, and scientific discovery and development. For more information on BIOCOM or the San Diego regional life sciences community, please visit the organization’s Web site at http://www.biocom.org, or contact our offices at 858-455-0300.
BIOCOM
CONTACT: Tim Ingersoll of BIOCOM, +1-858-455-0300
Web site: http://www.biocom.org/
